High Fees, Can't Beat the Market Even After Paying 10x More, What Exactly Are Top Hedge Funds Selling?
Original Article Title: Why People Are (Mostly) Wrong About Hedge Fund Returns
Original Article Author: @systematicls, Macro Analyst
Original Article Translation: AididiaoJP, Foresight News
Preface
Many people criticize hedge funds for their low returns, but they are actually making a conceptual mistake. Saying that hedge funds "can't beat the market" is like comparing the speed of a boat and a car, then complaining that the boat is slow on the highway—it's completely misidentifying the target.
Buying the S&P 500 index (i.e., the market factor) costs about 0.09% annually. The top hedge funds have annual fees in the range of 5%-8% (2/20 fee structure plus various expenses). The cost difference is up to 50-80 times.
If they were offering the same thing, then the investors would be foolish. But what they offer is indeed different, and the institutional investors putting in billions are not fools.
What they are buying is something that cannot be replicated with money: factor neutrality, high Sharpe ratio, large-scale and uncorrelated sources of returns. Once you understand this, you will understand the rationale behind the high fees and will no longer compare hedge funds to index funds.
Where Does the Demand Come From?
A common criticism is: "The S&P rose by 17% this year, but the hedge fund only earned 9.3%." This criticism may hold true for many hedge funds, as many are simply repackaged market fluctuations.
However, this completely misunderstands the product logic of top funds like Citadel/Millennium/Point72. Their goal is not to beat the market; that is not their job. It is unreasonable to compare a fund designed to be uncorrelated to a 100% stock benchmark, just as it is absurd to blame an insurance policy for not making money.
When you are managing a trillion-dollar pension fund and $600 billion is already in stocks, you are not lacking stock exposure; in fact, you have too much stock. What you truly need is something that can rise when the stock market falls (or at least not fall with it). You need risk diversification. More precisely, you want something that can rise regardless of the market conditions, outperforming cash.
Sound great, doesn't it? Feels like it would be expensive, right? Absolutely! True risk diversification is extremely costly because it is extremely rare!
Who Are the Competitors
The S&P 500's long-term Sharpe ratio is around 0.35-0.5, meaning that for every 1% fluctuation, you get a 0.35%-0.5% excess return. The Sharpe ratio of top global hedge funds is around 1.5-2.5 or even higher.
What we are talking about is maintaining a Sharpe ratio around 2 for decades, not only achieving returns unrelated to market fluctuations but also much lower volatility. These companies have very small drawdowns and quick recoveries.
Hedge funds are not a more expensive version of the same product but a completely different category. Top hedge funds offer two advantages that ETF/index products do not:
· Factor neutrality
· High Sharpe ratio
Why Factor Neutrality Matters
To understand the value of factor neutrality, look at this formula:
Return = Alpha + Beta × Factor Return + Random Error
· Alpha = Return from skill
· Beta = Exposure to systematic factors
· Factor Return = Return of market factors
· Random Error = Individual differences
The beta part can be replicated with publicly available factor portfolios. For replicable things, only replication costs should be paid. Replication is very cheap: market factor 0.03%-0.09%, style factors 0.15%-0.3%.
Alpha is what remains after deducting all replicable parts. By definition, alpha cannot be synthesized through factor exposure. This irreproducibility is the basis of premium.
Key insight: Beta is cheap because factor returns are public goods, with unlimited capacity. If the market goes up by 10%, all holders earn 10%, with no exclusivity. The S&P's return will not decrease because more people buy.
Alpha is expensive because it is a zero-sum game and has limited capacity. For every $1 earned in alpha, someone loses $1. The inefficiency of the market that generates alpha is limited in quantity and will disappear with capital inflows. A strategy with a Sharpe ratio of 2 at $100 million scale may only be left with 0.8 at $100 billion scale, as large-scale trading itself will affect prices.
Factor neutrality (where all systematic exposures' beta ≈ 0) is the only truly unreplicable source of returns. This is the rational basis for premium, not the return itself, but the inability to obtain such returns in other ways.
The Magic of High Sharpe Ratios
The high Sharpe ratio's compounding effect becomes apparent over time. A combination of two expected returns, both at 7%, with different volatilities (16% vs. 10%), shows vastly different outcomes after 20 years. The low-volatility combination halves the probability of loss, offering much better downside protection.
For institutions requiring stable income, this reliability is worth paying for.
Volatility not only affects the investment experience but also mathematically erodes long-term returns:
Geometric Mean Return ≈ Arithmetic Mean Return - (Volatility²/2)
This is called "volatility drag," where a high-volatility portfolio inevitably lags behind a low-volatility portfolio in the long run, even if the expected returns are the same.

The low-volatility combination eventually earns an additional $48 million, with wealth appreciation 16% higher, despite the "expected return" being the same. This is not a risk preference issue but a mathematical fact: volatility erodes wealth over time.
Think Like an Institutional Investor
Why are institutions willing to pay a 100x premium for a factor-neutral fund? Just look at the portfolio math, and you'll understand.
Consider a standard portfolio: 60% stocks + 40% bonds. Expected return 5%, volatility 10%, Sharpe ratio 0.5. Not bad, but the stock risk is high.
Adding a 20% factor-neutral hedge fund: expected return 10%, volatility 5%, Sharpe ratio 2.0, uncorrelated with stocks and bonds. New combination: 48% stocks + 32% bonds + 20% hedge fund.
Result: Expected return increases to 6%, volatility decreases to 8%, Sharpe ratio rises to 0.75 (a 50% improvement).
And this is just one fund. If you could find 2, 3 uncorrelated top funds? Now you understand why such assets are so valuable.
Institutions rush to invest in top-tier funds not because they don't know index funds are cheap but because they understand the mathematics at the portfolio level. They are not comparing fees but the portfolio efficiency fees bring.
How to Pick Funds Like an Institution
Suppose you want to find a product similar to a top-tier hedge fund, can't access Citadel/Millennium/Point72, but have plenty of time to research. How do you screen?
Focus on these key points:
Look at long-term factor exposure: Not just current, look at rolling data for several years. A truly factor-neutral fund should have exposure to market, industry, and style factors consistently close to zero. If the market beta fluctuates around 0.3, that's factor timing—potentially useful but not the product you want to buy.
Stress Testing: Everyone looks uncorrelated during a bull market. The real test is during a crisis: 2008, early 2020, 2022. If drawdowns align with the overall market, it's not true neutrality; it hides beta exposure.
Focus on Long-Term Sharpe Ratios: Short-term high Sharpe ratios may be luck-driven, but sustaining a high Sharpe ratio in the long term is unlikely to be purely luck. The Sharpe ratio is fundamentally a measure of return's statistical significance.
Abandon the Replication Idea: Factor ETFs can provide exposure to factors like value, momentum, with an annual cost of 0.15%-0.5%. However, this is not the same product. Factor ETFs are correlated to factors, whereas neutral funds are uncorrelated. This correlation structure is key. You need to seek actively managed products or alpha strategies.
Understanding Scarcity
After conducting the above research, you may realize that the number of products that fully meet all criteria is zero!
On a serious note, you may find close matches, but most likely they won't be able to accommodate institutional scale. For sovereign wealth funds managing trillions, investments of a few billion are insignificant.
Ultimately, you will understand that very few companies can maintain a Sharpe ratio above 2 at a scale of over 500 billion across multiple cycles. This is extremely challenging. Factor neutrality + large scale + long-term stability, having all three is extremely rare. This scarcity makes the premium reasonable for those who can invest.
Final Thoughts
Paying a 50-100x premium for a top-tier factor-neutral hedge fund has robust portfolio math behind it, which critics often overlook. Institutional investors are not fools; the real issue might be that too many funds charge top fees but only provide expensive beta that can be obtained for 0.15% annually.
(Note: Fund reports already show net returns after all fees have been deducted, so no additional deductions are needed.)
You may also like

Morning Report | OpenAI has submitted an S-1 registration statement draft to the U.S. SEC; Morpho completes $175 million financing

Galaxy Deep Research Report: How Hyperliquid's HIP-4 Upgrade Changes the Landscape of Prediction Markets?

Latest research from 13 top universities including Cornell University: The current state, challenges, and misconceptions of the fusion of Crypto and AI

Deconstructing Anthropic: The Best AI Company, Possibly Also a Type of Organizational Invention

Every exchange is a "Universal Exchange."

The counterattack of traditional finance: Alliance chains are quietly reviving

Pantera Capital Partner: How Tokenization is Restructuring the Private Equity and Early Investment Ecosystem?

Mastercard Launches Agent Pay for AI, Plans to Record AI Agent Payment Authorizations on Polygon
Mastercard launched Agent Pay for AI, a new payment protocol designed to help AI agents make small payments such as pay-per-use access to data and APIs. The system plans to record human-granted AI agent permissions on Polygon, focusing on verifiable authorization, identity, and payment controls.

Curve Deploys Llamalend v2 on Optimism With 250,000 OP Incentives
Curve launched Llamalend v2 on Optimism with 250,000 OP incentives from the Optimism Foundation. The upgrade expands Llamalend beyond its earlier crvUSD-focused model, adding broader collateral support, LlamaRisk market reviews, and the ability to use Curve LP tokens as collateral.

Raydium Old Liquidity Pool Reportedly Exploited, With $1.34 Million Moved to Ethereum and Tornado Cash
An old Raydium liquidity pool was reportedly exploited for around $1.34 million in USDC, RAY, and wSOL, with the stolen funds bridged to Ethereum and deposited into Tornado Cash. The incident highlights the tail risks of legacy DeFi pools, old contracts, and cross-chain fund laundering paths.

Kalshi Executive Challenges “SBF Backed AI Unicorns” Narrative, Says Leopold Aschenbrenner Was Key Figure
Kalshi executive John Wang questioned the “SBF backed AI unicorns” narrative, saying Leopold Aschenbrenner was the key figure behind major AI investment decisions.

New York Proposes Stricter Stablecoin Issuer Rules Aligned With Federal GENIUS Act
NYDFS proposed stricter stablecoin issuer rules aligned with the GENIUS Act, covering reserves, custody, redemption timelines, audits, and capital buffers.

CryptoQuant Says Bitcoin Profitable Supply Is Near 45% Pressure Zone as On-Chain Data Points to Market Repricing
CryptoQuant said Bitcoin’s profitable supply is nearing the 45% pressure zone, signaling rising market stress, unrealized losses, and a possible on-chain repricing phase.

Bitcoin Falls Below 200-Week Moving Average as On-Chain Data Shows Over Half of Supply in Loss
Bitcoin dropped below its 200-week moving average as on-chain data showed over 50% of circulating supply is now in loss, signaling rising market stress.

CFTC Reportedly Plans New Prediction Market Rules Focused on Manipulation Risk and Public Interest Review
The CFTC is reportedly preparing new prediction market rules focused on manipulation risk, public interest review, and retail trader protections.

Meet the new WEEX trial fund—your gateway to greater profits

WEEX Labs Lands at Dutch Blockchain Week: A Disruptive Crypto × AI Conversation Sets Sail in Amsterdam

SK Hynix Reportedly Plans U.S. ADR Listing as Early as August, With SEC Approval Possible in Late June
SK Hynix may pursue a U.S. ADR listing as early as August, with SEC approval reportedly possible in late June amid strong AI chip supply chain demand.
